ExaMD, Part of the ExaWizards Group, Forms a Business Alliance with CMIC HOLDINGS to Support Pharmaceutical Development
– Engaging in Clinical Research and Developing New AI-Driven Health and Medical Services –

ExaMD, a fully-owned subsidiary of ExaWizards Inc. (Minato-ku, Tokyo, Representative Director & President: Makoto Haruta, hereinafter ExaWizards) has announced a business alliance with CMIC HOLDINGS Co., Ltd. (Minato-ku, Tokyo, Representative Director & CEO: Kazuo Nakamura, hereinafter CMIC), a CRO (Contract Research Organization) supporting pharmaceutical development. This alliance will accelerate the development of new evidence-based AI applications in both the SaMD (Software as a Medical Device) and Non-SaMD fields.

Objectives of the Business Alliance
The development and dissemination of health and medical services based on clinical evidence is still in its infancy in Japan. Developing software services that use “AI biomarkers” derived from data collected through digital devices poses many distinct challenges.
Clinical development requires researchers to focus on factors such as the collection of digital biomarkers based on GCP (Good Clinical Practice), the establishment of clinical evaluation criteria, AI training based on validated medical data, and maintaining the accuracy required for medical services. It is also critical to maintain secure management and use of personal data via communication and distribution systems. So far, only a few players have been able to bring these solutions to fruition.
Demand for software services based on clinical evidence continues to grow. This business alliance expects to develop software services for consumers in the healthcare and general wellness markets, and may potentially create and expand new markets.
By leveraging their respective strengths, both companies can address these challenges and establish a system to develop high-quality AI services based on clinical evidence.

Initiatives by Both Companies
ExaMD was established in February 2024 as a subsidiary of ExaWizards, inheriting the health and medical AI product and service business. The company excels at multimodal processing technologies (voice, video, etc.). Their first initiative involved developing AI services for the health and medical markets, including a diagnostic support program for dementia that used conversational voice AI (SaMD) and cognitive function measurement software (Non-SaMD).
Looking ahead, ExaMD will focus on obtaining manufacturing and marketing licenses, clinical trial capabilities, and constructing communication and distribution functions for future SaMD development. By leveraging AI biomarkers related to lifestyle behaviors, ExaMD plans to develop and market services that detect and predict health states and risks.

CMIC HOLDINGS started the first CRO business in Japan in 1992. The company provides comprehensive pharmaceutical support services, from development to manufacturing, sales, and marketing. CMIC also assists overseas companies in entering the Japanese market, conducts clinical trials in Asia, and supports pharmaceutical development and manufacturing in the US and Japan. They offer new healthcare solutions to individuals and local governments to maximize individual health value through their PHVC (Personal Health Value Creator) model. CMIC provides extensive support for SaMD development from development strategy and regulatory consulting to clinical trial operations.

Company Overview of CMIC HOLDINGS
Company Name: CMIC HOLDINGS Co., Ltd.
Location: 1-1-1 Shibaura, Minato-ku, Tokyo
Established: March 1985
Representative: CEO Kazuo Nakamura
Business Areas: CRO Business, CDMO Business, Market Solutions Business, Site Support Solutions Business, Healthcare Revolution Business
URL: https://www.cmicgroup.com/

【ExaMD Corporate profile】
Company name: ExaMD Inc.
Location: 4-2-8 Shibaura, Minato-ku, Tokyo, 5F, Sumitomo Realty & Development Mita Twin Building East
Established: February 1, 2024 (scheduled) 
Representative: Koji Hazama, Representative Director
Business: Planning, development, sales, and alliance of products and services using multi-modal AI technology to solve social issues related to healthcare 
URL: https://examd.com/

【ExaWizards Corporate profile】
Company name: ExaWizards Inc.
Location: 4-2-8 Shibaura, Minato-ku, Tokyo, 5F, Sumitomo Realty & Development Mita Twin Building East
Established: February 2016
Representative: Makoto Haruta, Representative Director & President
Business: Industrial innovation and resolution of social issues via AI service development
URL: https://exawizards.com/

＜Media Contact＞
ExaWizards Inc. Public Relations: publicrelations@exwzd.com